As reported in Healio, UCLA professor Robert M. Prins, PhD, has received a $750,000 grant from the Brain Tumor Funders’ Collaborative to support his research of immunotherapies for brain therapies. Prins is a professor of neurosurgery and molecular and medical pharmacology at David Geffen School of Medicine at UCLA, immunologist at UCLA Jonsson Comprehensive Cancer Center, and research with Parker Institute for Cancer Immunotherapy Center at UCLA. Prins and team are now studying whether checkpoint blockade in conjunction with a personalized dendritic cell vaccine will benefit patients with glioblastoma, a form of malignant glioma previously thought to be shielded from the immune system. The research community has made limited advances against gliomas over the past 20 years. They are an aggressive form of brain cancer.